The purpose of this research study is to test and adapt new techniques for performing magnetic resonance imaging (MRI). MRI provides pictures of the inside of the body and information about chemicals the body makes. Here are some examples of what we hope to accomplish:

1. Adapt MRI techniques used at other institutions for use on CHOP MRI scanners

2. Increase the amount of information learned from each MRI image

The research sequences involve changing the settings of the magnetic resonance scanner. By research sequences we mean that they are not approved by the US Food and Drug Administration (FDA) for clinical use. The data we obtain will help the FDA evaluate whether or not they can eventually approve the sequences for clinical use.

We are seeking to enroll healthy volunteers, 18 years of age and above. Pregnant females excluded for safety purposes.

The purpose of this study is to identify and engage young black or hispanic/latino men (male sex at birth, but gender identity male, transfemale, or gender nonconforming) (YBLMSM/transwomen) in Philadelphia, PA, Baltimore, MD and Washington, DC in HIV and substance use prevention using a new Mobile-enhanced Engagement intervention (app that reminds you to take your meds, reminds you of your medical appointments, etc.). There are three different parts to this study: 1) respondent driven sampling (RDS); 2) Randomized Control Trial (RCT): MEI vs Standard of Care for HIV+ youth; and 3) PrEP RCT: Pre Exposure Prophylaxis - Mobile-enhanced Engagement Intervention (PrEP-MEI) vs. Standard PrEP referral;. It is possible to participate in only the RDS, the RDS and the AIM 3 PrEP RCT, or the RDS and AIM 2 RCT studies.

The RDS study involves 2 study visits lasting up to 1 month of participation where participants will be asked to complete an optional rapid HIV test (oral or fingerstick) or viral load testing (blood draw), web-based survey (on past sexual and HIV experiences), recruit your peers to participate in the study, and complete a post-recruitment survey. YBLMSM/transwomen and cisgender females 15-24 years may participate in RDS, but the following study portions are only for YBLMSM/transwomen:

People who successfully complete the RDS portion of the study may be asked to participate in an additional study visit of an audio-recorded focus group or interview.

The RCT study involves 6 study visits (5 in person, 1 phone) and lasts 18 months. Participants will be assigned to one of two groups receiving different HIV supportive interventions: 1) HIV case management with a Mobile-enhanced Engagement Intervention (MEI), or 2) standard of care HIV case management where a case manager will remind you of medical appointments. If you are assigned to the first group (MEI), you will be asked to use the MEI mobile app or web-browser version of the app during the study period. Participants will be asked to complete a web-survey (on past sexual and HIV experiences), HIV Antibody and Viral load testing (blood draw), urine drug testing, and allow the researchers to access your medical charts for HIV and STI testing results. You may also be asked to participate in audio-recorded in-depth interviews.

The PrEP RCT study involves 5 study visits (5 in person, 1 phone) and lasts 18 months. Participants will be assigned to one of two groups receiving different PrEP and substance use supportive interventions: 1) PrEP case management with a Mobile-enhanced Engagement Intervention (MEI-PrEP), or 2) standard PrEP referrals to services. If you are assigned to the first group (MEI-PrEP), you will be asked to use the MEI-PrEP mobile app or web-browser version of the app during the study period. Participants will be asked to complete a web-survey (on past sexual and HIV experiences), HIV Antibody (blood draw or 2 rapid OraQuick tests in place of serologic 4th generation testing when 4th generation testing is not available) and Viral load testing (blood draw), urine drug testing, use the MEI-PrEP mobile app or web-browser version of the app, and allow the researchers to access your medical charts for HIV and STI testing results. You may also be asked to participate in audio-recorded in-depth interviews.

Cure Glomerulonephropathy Network (CureGN) is a multi-year study of 2,400 children and adults with four rare glomerular (kidney) diseases at over 50 centers in the US, Canada, and Italy. The purpose of CureGN is to create a patient research network to learn about four major causes of glomerular disease : 1. Minimal Change Disease (MCD) 2. Focal Segmental Glomerulosclerosis (FSGS) 3. Membranous Nephropathy (MN) 4. IgA Nephropathy (IgAN)

The purpose of this study is to test if the CD19 CAR T cell product tisagenlecleucel (also referred to as CTL019, or Kymriah™) is safe and has beneficial effects in children and young adults who have newly diagnosed high-risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL) that remains MRD-positive after 2 cycles of chemotherapy. The study is enrolling children and young adults between the ages of 1-25 who have received induction and consolidation chemotherapy for HR B-ALL but were still found to have remaining disease (MRD). If you agree to join in this study, you will get one dose of the tisagenlecleucel cells administered by intravenous infusion and be followed for leukemia response. This study also involves blood draws and assessments. Reimbursement for travel may be provided. If you have questions or would like to learn more about the study, please contact the Cancer Immunotherapy Program at (215) 425-7193. The Principal Investigator is Dr. Shannon Maude and the Immunotherapy Nurse Navigator is Brooke Leibfreid, RN.

A thorough review of outcome measures that assess disease progression has not been established for any of the subcategories of Alexander disease. These results will be crucial to our understanding of disease presentation and progression. Providing this information about the pathophysiology will allow for effective development of clinical trials to test therapies and the future use of neuroprotective agents in children. 

Collect data and blood samples to make observations and determinations about rate and severity of graft-versus-host disease in HCT patients. 

Patients with no available curative treatment options with leukemia are eligible to participate in this study to test an experimental approach called gene transfer that involves B cells. This study will take the patients white blood cells - T cells - and change them to turn against the cancer.

This study will test whether supplemental oxygen therapy, a common post-discharge treatment for BPD, improves outcomes. Enrolled infants, between the ages of 34-44 weeks Post Menstrual Age, with moderate or severe BPD, will be randomly assigned to higher or lower oxygen saturation target ranges. The study intervention will begin in the hospital and will continue at home until 6 months Corrected Age.

The purpose of this research study is to 1) validate the use of surveys such as fatigue scales, Mitochondrial Disease scales, and quality of life scales, 2) validate clinical exams, such as muscle strength tests, and the 6 minute walk test, and 3) to define the natural history of the disease in the Mitochondrial Disease patient population.

The purpose of this research study is to identify genes that are involved in the development of Inflammatory Bowel Disease (IBD) at a young age (less than 8 years of age). This is a case-control study of IBD patients which compares children with symptoms and/or diagnosis of IBD.